000168701 001__ 168701
000168701 005__ 20240917145525.0
000168701 0247_ $$2doi$$a10.1016/j.radonc.2021.04.016
000168701 0247_ $$2pmid$$apmid:33940087
000168701 0247_ $$2ISSN$$a0167-8140
000168701 0247_ $$2ISSN$$a1879-0887
000168701 0247_ $$2altmetric$$aaltmetric:106390463
000168701 037__ $$aDKFZ-2021-01009
000168701 041__ $$aEnglish
000168701 082__ $$a610
000168701 1001_ $$aRöhrich, Manuel$$b0
000168701 245__ $$a68Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of Adenoid Cystic Carcinomas - imaging analysis and histological validation.
000168701 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2021
000168701 3367_ $$2DRIVER$$aarticle
000168701 3367_ $$2DataCite$$aOutput Types/Journal article
000168701 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1726577701_16365
000168701 3367_ $$2BibTeX$$aARTICLE
000168701 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000168701 3367_ $$00$$2EndNote$$aJournal Article
000168701 500__ $$a2021 May 1;160:192-201
000168701 520__ $$aAdenoid cystic carcinomas (ACCs) are rare epithelial tumors mostly situated in the head and neck region and characterized by infiltrative growth. The tumor stroma of ACCs includes cancer-associated fibroblasts (CAFs) expressing Fibroblast Activation Protein (FAP), a new target for positron emission tomography (PET) imaging. Here we describe the value of PET/ computed tomography (PET/CT) imaging using 68Ga-labelled FAP-Inhibitors (68Ga-FAPI-PET/CT) and their clinical potential for staging and radiotherapy planning in 12 ACC patients (7 primary, 5 recurrent).Patients underwent contrast enhanced staging CT (ceCT) and magnetic resonance imaging (ceMRI) before 68Ga-FAPI - PET/CT. PET-scans were acquired 10, 60 and 180 minutes after administration of 150-250 MBq of 68Ga-labelled FAPI tracers. SUVmax and SUVmean values of ACCs and healthy organs were obtained using a 60% of maximum iso-contour. FAP and alpha smooth muscle actin (α-SMA) immunohistochemistry was performed in 13 cases (3 with and 10 without 68Ga FAPI-PET/CT). Staging and radiotherapy planning based on 68Ga-FAPI-PET/CT versus ceCT/MRI alone were compared.We observed elevated tracer uptake in all ACCs. Immunohistochemistry showed FAP-expressing CAFs in the tumor. Compared to conventional staging, 68Ga-FAPI-PET/CT led to upstaging in 2/12 patients and to detection of additional metastases in 3 patients, thus in total 42% of patients had their staging altered. Moreover, 68Ga-FAPI PET improved the accuracy of target volume delineation for radiotherapy, as compared to CT and MRI.68Ga-FAPI-PET/CT is a promising imaging modality for ACC, increasing the accuracy of staging exams and radiotherapy planning volumes, as compared conventional to CT and MRI.
000168701 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000168701 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000168701 650_7 $$2Other$$aACC
000168701 650_7 $$2Other$$aAdenoid cystic carcinoma
000168701 650_7 $$2Other$$aFAP
000168701 650_7 $$2Other$$aFibroblast Activation Protein
000168701 650_7 $$2Other$$aPositron Emission Tomography
000168701 650_7 $$2Other$$aRadiotherapy
000168701 650_7 $$2Other$$aStaging
000168701 650_7 $$2Other$$aTNM
000168701 650_7 $$2Other$$aalpha SMA
000168701 7001_ $$aSyed, Mustafa$$b1
000168701 7001_ $$aLiew, Dawn P$$b2
000168701 7001_ $$0P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94$$aGiesel, Frederik L$$b3
000168701 7001_ $$aLiermann, Jakob$$b4
000168701 7001_ $$aChoyke, Peter L$$b5
000168701 7001_ $$0P:(DE-He78)32977c5abc127b0373ece54294a41f63$$aWefers, Annika K$$b6
000168701 7001_ $$aRitz, Thomas$$b7
000168701 7001_ $$0P:(DE-He78)fb880577e0932ea92d81172263f291f0$$aSzymbara, Marina$$b8
000168701 7001_ $$aSchillings, Lisa$$b9
000168701 7001_ $$aHeger, Ulrike$$b10
000168701 7001_ $$aRathke, Hendrik$$b11
000168701 7001_ $$aKratochwil, Clemens$$b12
000168701 7001_ $$0P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aHuber, Peter E$$b13$$udkfz
000168701 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b14
000168701 7001_ $$aDebus, Jürgen$$b15
000168701 7001_ $$aKauczor, Hans-Ulrich$$b16
000168701 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, Uwe$$b17
000168701 7001_ $$0P:(DE-HGF)0$$aAdeberg, Sebastian$$b18
000168701 773__ $$0PERI:(DE-600)1500707-8$$a10.1016/j.radonc.2021.04.016$$gp. S0167814021062137$$p192-201$$tRadiotherapy and oncology$$v160$$x0167-8140$$y2021
000168701 909CO $$ooai:inrepo02.dkfz.de:168701$$pVDB
000168701 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000168701 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)32977c5abc127b0373ece54294a41f63$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000168701 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb880577e0932ea92d81172263f291f0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000168701 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000168701 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000168701 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000168701 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$aExternal Institute$$b18$$kExtern
000168701 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000168701 9130_ $$0G:(DE-HGF)POF3-319H$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vAddenda$$x0
000168701 9141_ $$y2021
000168701 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-01-31$$wger
000168701 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-31
000168701 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-31
000168701 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-31
000168701 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-31
000168701 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-31
000168701 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-31
000168701 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-31
000168701 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-31
000168701 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-31
000168701 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bRADIOTHER ONCOL : 2019$$d2021-01-31
000168701 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-31
000168701 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-31
000168701 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-01-31
000168701 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x0
000168701 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x1
000168701 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x2
000168701 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x3
000168701 980__ $$ajournal
000168701 980__ $$aVDB
000168701 980__ $$aI:(DE-He78)HD01-20160331
000168701 980__ $$aI:(DE-He78)B300-20160331
000168701 980__ $$aI:(DE-He78)E055-20160331
000168701 980__ $$aI:(DE-He78)E060-20160331
000168701 980__ $$aUNRESTRICTED